Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ANTH under value - 5 Stocks Under $10 Set to Trade Higher in November
http://www.thestreet.com/story/11754495/4/5-stocks-under-10-set-to-trade-higher-in-november.html
imo this will take up to 52 weeks, ANTH wrote Patients will be treated in the controlled part of each study for 52 weeks after which they will have the option to receive additional treatment as part of an open-label, long-term, follow-up safety study. btw can they disclose partial results before meeting the endpoint?
MGIC Investment is Among the Companies in the Thrifts & Mortgage Finance Industry With the Lowest Price to Forward Sales (MTG, RDN, FBC, RVSB, TSBK)
http://www.mysmartrend.com/news-briefs/radian/mgic-investment-among-companies-thrifts-mortgage-finance-industry-lowest-price-fo
Written on Thu, 09/27/2012 - 6:22am
By Amy Schwartz
Below are the three companies in the Thrifts & Mortgage Finance industry with the lowest price to forward sales ratios. The ratio shows how much Wall Street values every dollar of the company's future sales and is useful in comparing comparable companies. Generally the lower the ratio, the more attractive the investment.
MGIC Investment ranks lowest with a a price to forward sales ratio of 0.26. Radian is next with a a price to forward sales ratio of 0.61. Flagstar Bancorp ranks third lowest with a a price to forward sales ratio of 0.66.
Riverview Bancorp follows with a a price to forward sales ratio of 0.70, and Timberland Bancorp rounds out the bottom five with a a price to forward sales ratio of 1.15.
SmarTrend recommended that subscribers consider buying shares of Radian on June 18th, 2012 as our technology indicated a new Uptrend was in progress when shares hit $2.79. Since that recommendation, shares of Radian have risen 56.6%. We continue to monitor Radian for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.
good find but that also means that it could last up to one year before they disclose any (positive) results from phase III trial?
last time sept 2011 it took less than 3 months to double from 2 to 4 dollars
for sure it sounds promising
who cares? there has been also a downgrade alert by 15/08/12 at a share price 1.31 and now we are climbing steady to 2 dollars
MGIC Releases Monthly Operating Statistics
http://ih.advfn.com/p.php?pid=nmona&article=54122275
it seems like invisible forces are holding this down
Stock to Watch: MGIC Investment Up 7.5% (MTG)
Written on Fri, 09/07/2012 - 12:48pm
By Amy Schwartz
MGIC Investment (NYSE:MTG) is one of today's best performing low-priced stocks, up 7.5% to $1.37 on 1.0x average daily volume. MGIC Investment has traded 7.5 million shares thus far today, vs. average volume of 7.5 million shares per day. The stock has outperformed the Dow (7.5% to the Dow's -0.1%) and outperformed the S&P 500 (7.5% to the S&P's 0.2%) during today's trading.
MGIC Investment Corporation, through its subsidiary, provides private mortgage insurance coverage in the United States. The Company's customers include thrifts, mortgage bankers and brokers, commercial banks, credit unions, and other lending institutions. The Company also provides, through subsidiaries, underwriting and contract services related to home mortgage lending.
Potential upside of 3.8% exists for MGIC Investment, based on a current level of $1.36 and analysts' average consensus price target of $1.42. MGIC Investment shares should first meet resistance at the 50-day moving average (MA) of $1.82 and find additional resistance at the 200-day MA of $3.24.
MGIC Investment share prices have moved between a 52-week high of $5.15 and a 52-week low of $0.66 and are now trading 107% above that low price at $1.36 per share. The 200-day and 50-day moving averages have moved 0.76% lower and 4.56% lower over the past week, respectively.
SmarTrend recommended that subscribers consider buying shares of MGIC Investment on August 8th, 2012 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $1.07. Since that recommendation, shares of MGIC Investment have risen 18.7%. We continue to monitor MTG for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.
March 9, 2012Anthera Halts VISTA-16 Clinical Study Due to Lack of Efficacy Following Recommendation by the Independent Data Safety Monitoring Board
HAYWARD, Calif., March 9, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced that the VISTA-16 Data Safety Monitoring Board (DSMB) has recommended stopping the VISTA-16 clinical study due to a lack efficacy that could not be reasonably overcome in the remainder of the trial. The DSMB's recommendation was based on a review of the totality of the safety and efficacy data available for the VISTA-16 clinical study.
"Based on all the evidence we have seen regarding varespladib and secretory phospholipase and in light of previous study results, we were surprised by the recommendation from the DSMB," said Stephen Nicholls, MD, Cardiovascular Director of the Cleveland Clinic Coordinating Center for Clinical Research and chairman of the executive committee overseeing the VISTA-16 trial. "We believed that the study was coming along as expected, and this new information was totally unexpected and disappointing given the potential benefits of this drug."
Anthera has closed enrollment in the phase 3 VISTA-16 clinical study and informed all investigators to remove patients from therapy immediately. "While the Data Safety Monitoring Board information we received today was both surprising and disappointing, our focus is on the best interests of patients and making sure all this information is communicated to appropriate medical and regulatory authorities as quickly as possible," said Paul F. Truex, Anthera's President and Chief Executive Officer.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.
Gary has AEZS gotten shareholder-approval to do the R/S?
currently opus point healthcare fund has bought more than 4 mill. shares
http://ih.advfn.com/p.php?pid=nmona&article=53956013
"multiple" was sarcasm, but r/s is in talks or imminent to meet nasdq-requirements
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77654491
and please also read gary´s excellent comments on this board
first of multiple R/S has been executed ;o)
three bucks possible this year
http://seekingalpha.com/article/789171-why-i-bought-mgic-investment-corp-for-a-trade?source=feed
thanks and cheers
means much more gains for the clever ones :o)
mate would you please so kind to translate all of yours "*>>*°><>>?=?!)()_//"
all imo
Hot Stock: AEterna Zentaris, Shares Gain 8.8% (AEZS)
Written on Tue, 07/24/2012 - 12:46pm
By James Quinn
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing penny stocks, up 8.8% to $0.47 on 1.2x average daily volume. Thus far today, AEterna Zentaris has traded 1.3 million shares, vs. average volume of 1.0 million shares per day. The stock has outperformed the Dow (8.8% to the Dow's -1.1%) and outperformed the S&P 500 (8.8% to the S&P's -1.2%) during today's trading.
In the past 52 weeks, AEterna Zentaris share prices have been bracketed by a low of $0.38 and a high of $2.25 and are now at $0.47, 23% above that low price. The 200-day and 50-day moving averages have moved 1.25% lower and 1.62% lower over the past week, respectively.
Potential upside of 44.2% exists for AEterna Zentaris, based on a current level of $0.47 and analysts' average consensus price target of $0.68. The stock should run into initial resistance at its 50-day moving average (MA) of $0.47 and subsequent resistance at its 200-day MA of $1.23.
AEterna Zentaris Inc is a biopharmaceutical company focused in oncology and endocrine therapy. The Company's portfolio includes an orally-active inhibitor for multiple cancers, as well a product marketed for in vitro fertilization. AEterna Zentaris also develops and sells active ingredients, specialty chemicals, cosmetic, and nutritional products.
SmarTrend is tracking the current trend status for AEterna Zentaris and will alert subscribers who have AEZS in their portfolio or watchlist when shares have changed trend direction.
http://www.mysmartrend.com/news-briefs/technical-analysis/hot-stock-aeterna-zentaris-shares-gain-88-aezs-0
agreed. imo they are on track, there is much more in the pipeline
should go as high as to meet the requirements again to stay at nasdaq - $1.00 per share for a minimum of 10 consecutive business days
exceptional qualified comment, will help to make decisions :o)
c o r r e c t i o n
MONTREAL – Aeterna Zentaris Inc. was once a high-flying drug maker whose $20 share price rested on its plan to use shark cartilage to treat cancer.
Today, the Quebec City company is a beaten-down penny stock struggling to keep its U.S. listing and bring its pipeline of products to market.
Next month, investors will convene at the Montreal offices of law firm Norton Rose Canada to vote on a special resolution that would consolidate Aeterna’s common shares in an attempt to avoid a potential delisting on the Nasdaq. The stock currently trades at about 45¢, below the requirements for a continued presence on the exchange.
Aeterna management wants to stay listed to be able to raise money more easily. And it believes that the possible increase in the share price through consolidation may renew investor interest in the company, specifically from institutional investors who have formal or informal policies that prevent them from buying penny stocks.
Related
Picking winners in biotech
Canada's most disappointing tech stocks
If the company loses its Nasdaq listing, accessing capital becomes that much more difficult, said one Toronto-based analyst who follows the company. It’s a highly liquid stock that trades a lot in that market. The company is also listed on the Toronto Stock Exchange but volumes are lower.
“Really what I think is most important here is for the management team to build back its credibility,” the analyst said Monday. “Drug development is a difficult business. And they brought two drugs very close to the finish line and they both failed.”
The most recent setback for Aeterna chief executive Juergen Engel came April 2, when he announced that a clinical trial evaluating the company’s perifosine product for treatement of late stage colorectal cancer showed it didn’t work as hoped.
The company subsequently lost two-thirds of its market value that day. It now faces at least one class action lawsuit in the United States as plaintiffs allege Mr. Engel and chief financial officer Dennis Turpin misled investors about the timing and success of the clinical trial. A judge must certify the suit before it is allowed to proceeed.
Aeterna Zentaris had total assets of US$74.1-million and liabilities of US$82.7-million as of the end of March this year, according to a recent investor presentation.
Still, analysts like the company’s deep pipeline of products. And they say its decision to move forward with perifosine trials for the treatment of another condition, multiple myeloma, has some logic to it because it’s a minimal investment to push it to commercialization.
Until those drugs bear more fruit however, the more immediate concern is simply avoiding a fall of its stock to “over-the-counter” bulletin board status.
http://business.financialpost.com/2012/07/16/aeterna-fights-to-hang-on-to-nasdaq-listing/
i don´t see any hint of a r/s and if i recall correctly they never had done a r/s, even when the shareprice dropped in 2008/2009 to same levels as for today.
If you are annoyed about the sp, call one of the lawyers who try to sue the company.
or call CEO Dr. Engel directly or listen him for future plans
if they make progress in developing their products like antx today announced, then there will be no need for r/s or whatever. i´m sure they will succeed
excellent interpretation Gary. I was listening but must say that I´ve not understood all details. but all in all it sounds absolutely optimistic
who´s interested listening the presentation, here is the link, hope it works
http://wsw.com/webcast/jmp18/aezs/
Metal Storm wins US$1.48m contract from Colt Canada
http://www.proactiveinvestors.com.au/companies/news/31224/metal-storm-wins-us148m-contract-from-colt-canada-31224.html
hope you enjoy your trip. Alternative energy will take place, it´s always a question of time, maybe in 50 or 150 years. Who knows?
But - in our small thinking timeframe pcx can make billions of big money and so they should do
Stanner as you all know has germany as one of the first has switched to "green energy" especially after the accident in japan. but why do not invest in coal as long it is with margin (and hopefully sure)? i´m sure nobody can change energy-supply in your country from today until tomorrow and this is good also imo
partial agreed. it depends from the price development of gas as they said. would be nice to hear something positive from management. nevertheless this stock is currently cheap imo. will buy more if it dips
buy recommendation for pcx from german stockboard
http://www.investorsinside.de/ein-blick-in-den-us-kohlesektor/
they also mention to have a look at the UNG (United States Natural Gas ETF)
Aeterna Zentaris to Present at 7th Annual JMP Securities Healthcare Conference in New York
http://ih.advfn.com/p.php?pid=nmona&article=53058365
good point, that´s my view too
Aeterna Zentaris: Partner Yakult Initiates Phase 1 Trial in Multiple Myeloma with Perifosine in Japan
QUEBEC CITY, June 28, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Japanese partner Yakult Honsha ("Yakult") (Tokyo: 2267) has initiated a Phase 1 trial in multiple myeloma, a form of blood cancer, with perifosine, the Company's oral Akt/PI3K inhibitor drug. Yakult, who are sponsoring and conducting this trial in Japan, reported that a first patient has been treated with perifosine.
This is an open-label, two step Phase 1 trial in which perifosine is combined with bortezomib (Velcade®) and dexamethasone in patients with refractory multiple myeloma who had previously been treated with bortezomib. The trial is expected to include a total of 18 patients (6 in step 1 and 12 in step 2). Patients will receive perifosine daily (50 mg, Days 1-21) in combination with bortezomib (1.3 mg/m2, Days 1, 4, 8 and 11) and dexamethasone (20 mg, Days 1, 2, 4, 5, 8, 9, 11 and 12) according to a three-week cycle (21 days ± 3 days). The primary endpoint is safety while secondary endpoints include response rate, progression-free survival, and time to tumor progression.
Juergen Engel, PhD, President and CEO at Aeterna Zentaris stated, "We would like to thank our partner Yakult for their close collaboration in initiating this important Phase 1 trial in multiple myeloma which is necessary at this time in order to comply with Japan's specific registration requirements. Perifosine, also currently in a Phase 3 trial in other parts of the world in multiple myeloma for which we expect to reach an interim analysis in the first quarter of next year, remains a key component of our deep pipeline focused on providing novel, targeted treatment options for cancer patients facing unmet medical needs".
About Perifosine
Perifosine is a novel, oral anticancer treatment that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. It has been granted orphan drug and orphan medicinal product designations from both the FDA and EMA for multiple myeloma. Perifosine has also received Fast Track designation from the FDA and positive Scientific Advice from the EMA with results from the Phase 3 trial in multiple myeloma expected to be sufficient for registration in Europe, as well as in North America. Perifosine is also being explored in combination therapy and in monotherapy in other cancer indications. Aeterna Zentaris holds rights to perifosine for North America and Europe, while rights have been licensed to Yakult Honsha for Japan, to Handok for Korea, and to Hikma Pharmaceuticals for the MENA (Middle East and North Africa) region.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For more information please visit www.aezsinc.com.
Forward-Looking Statements
http://ih.advfn.com/p.php?pid=nmona&article=52924279
positive results disclosed
maybe they will release data today after trading or tomorrow - we will see
good job! AEZS currently underestimated, more to come from ENDO Annual Meeting and Expo next days
http://ih.advfn.com/p.php?pid=nmona&article=52766126